- Home
- THAR vs TOVX Comparison
THAR vs TOVX Comparison
Compare THAR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- TOVX
- Stock Information
- Founded
- THAR 2017
- TOVX 2001
- Country
- THAR United States
- TOVX United States
- Employees
- THAR 3
- TOVX N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- TOVX Health Care
- Exchange
- THAR Nasdaq
- TOVX Nasdaq
- Market Cap
- THAR 16.8M
- TOVX 4.5M
- IPO Year
- THAR 2022
- TOVX 2006
- Fundamental
- Price
- THAR $3.14
- TOVX $0.41
- Analyst Decision
- THAR Strong Buy
- TOVX Hold
- Analyst Count
- THAR 1
- TOVX 1
- Target Price
- THAR $17.00
- TOVX N/A
- AVG Volume (30 Days)
- THAR 29.4M
- TOVX 1.0M
- Earning Date
- THAR 11-06-2025
- TOVX 11-11-2025
- Dividend Yield
- THAR N/A
- TOVX N/A
- EPS Growth
- THAR N/A
- TOVX N/A
- EPS
- THAR N/A
- TOVX N/A
- Revenue
- THAR N/A
- TOVX N/A
- Revenue This Year
- THAR N/A
- TOVX N/A
- Revenue Next Year
- THAR N/A
- TOVX N/A
- P/E Ratio
- THAR N/A
- TOVX N/A
- Revenue Growth
- THAR N/A
- TOVX N/A
- 52 Week Low
- THAR $0.95
- TOVX $0.37
- 52 Week High
- THAR $9.08
- TOVX $4.29
- Technical
- Relative Strength Index (RSI)
- THAR 48.05
- TOVX 46.51
- Support Level
- THAR $2.75
- TOVX $0.38
- Resistance Level
- THAR $3.46
- TOVX $0.45
- Average True Range (ATR)
- THAR 1.23
- TOVX 0.02
- MACD
- THAR -0.32
- TOVX 0.00
- Stochastic Oscillator
- THAR 6.16
- TOVX 44.00
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.